Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 1, 2015, Pages 41-53

  Devineni, Damayanthi ^a   Manitpisitkul, Prasarn ^a   Vaccaro, Nicole ^a   Bernard, Apexa ^a   Skee, Donna ^a   Mamidi, Rao N V S ^a   Tian, Hong ^a   Weiner, Sveta ^a   Stieltjes, Hans ^b   Sha, Sue ^a   Rothenberg, Paul ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

Canagliflozin; Digoxin; Drug drug interaction; Oral contraceptive; Warfarin

Indexed keywords

CANAGLIFLOZIN; DIGOXIN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; WARFARIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG COMPETITION; DRUG EXCRETION; DRUG EXPOSURE; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPOGLYCEMIA; INTERNATIONAL NORMALIZED RATIO; MALE; MAXIMUM PLASMA CONCENTRATION; MULTIPLE DRUG DOSE; NAUSEA; NORMAL HUMAN; OPEN STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN;

EID: 84963936051     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202157     Document Type: Article

References (38)

1. Cefalu WT, Richards RJ, Melendez-Ramirez LY. Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects. Cleve Clin J Med. 2009; 76 (Suppl 5): S39-S47. CrossRef PubMed
2. Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman BAmerican Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009; 32: 193-203. CrossRef PubMed
3. Canagliflozin (Invokana™) Prescribing Information. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2013. Accessed on November 29. 2013. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/204042s000lbl.pdf.
4. Canagliflozin (Invokana™) Summary of Product Characteristics. Beerse, Belgium: Janssen-Cilag International NV. 2013. Accessed on December 16, 2013. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/002649/WC500156456.pdf.
5. Lee YJ, Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl. 2007; 72: S27-S35. CrossRef PubMed
6. Polidori D, Sha S, Mudaliar S, Ciaraldi TP, Ghosh A, Vaccaro N, Farrell K, Rothenberg P, Henry RR. Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study. Diabetes Care. 2013; 36: 2154-2161. CrossRef PubMed
7. Skouby SO. Hormonal contraception in obesity, the metabolic syndrome, and diabetes. Ann N Y Acad Sci. 2010; 1205: 240-244. CrossRef PubMed
8. Moreno I, Quiñones L, Catalán J, Miranda C, Roco A, Sasso J, Tamayo E, Cáceres D, Tchernitchin AN, Gaete L, Saavedra I. [Influence of CYP3A4/5 polymorphisms in the pharmacokinetics of levonorgestrel: A pilot study]. Biomedica. 2012; 32: 570-577. CrossRef PubMed
9. Wang B, Sanchez RI, Franklin RB, Evans DC, Huskey SE. The involvement of CYP3A4 and CYP2C9 in the metabolism of 17 alpha-ethinylestradiol. Drug Metab Dispos. 2004; 32: 1209-1212. CrossRef PubMed
10. Zamek-Gliszczynski MJ, Day JS, Hillgren KM, Phillips DL. Efflux transport is an important determinant of ethinylestradiol glucuronide and ethinylestradiol sulfate pharmacokinetics. Drug Metab Dispos. 2011; 39: 1794-1800. CrossRef PubMed
11. Davis J, Langdon G, Layton G, Chong CL, Ndongo MN, Vourvahis M. The effect of lersivirine, a nextgeneration NNRTI, on the pharmacokinetics of midazolam and oral contraceptives in healthy subjects. Eur J Clin Pharmacol. 2012; 68: 1567-1572. CrossRef PubMed
12. Food and Drug Administration (FDA). Guidance for industry drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. 2012. Accessed on November 29, 2013. Available at: http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm292362.pdf.
13. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133: 160s-198s. PubMed
14. Hirsh J, Fuster V, Ansell J, Halperin JLAmerican Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation. 2003; 107: 1692-1711. CrossRef PubMed
15. Chan E, McLachlan A, O'Reilly R, Rowland M. Stereochemical aspects of warfarin drug interactions: use of a combined pharmacokinetic-pharmacodynamic model. Clin Pharmacol Ther. 1994; 56: 286-294. CrossRef PubMed
16. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther. 1997; 73: 67-74. CrossRef PubMed
17. de Lannoy IA, Silverman M. The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin. Biochem Biophys Res Commun. 1992; 189: 551-557. CrossRef PubMed
18. Hamberg AK, Wadelius M, Lindh JD, Dahl ML, Padrini R, Deloukas P, Rane A, Jonsson EN. A pharmacometric model describing the relationship between warfarin dose and INR response with respect to variations in CYP2C9, VKORC1, and age. Clin Pharmacol Ther. 2010; 87: 727-734. CrossRef PubMed
19. Food and Drug Administration (FDA). Guidance for Industry, Bioanalytical Methods Validation. 2001. Accessed on November 25, 2013. Available at: http://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf.
20. Shah VP, Midha KK, Findlay JW, Hill HM, Hulse JD, McGilveray IJ, McKay G, Miller KJ, Patnaik RN, Powell ML, Tonelli A, Viswanathan CT, Yacobi A. Bioanalytical method validation - a revisit with a decade of progress. Pharm Res. 2000; 17: 1551-1557. CrossRef PubMed
21. Viswanathan C, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, Shah VP, Skelly JP, Swann PG, Weiner R. Workshop/conference report - quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. AAPS J. 2007; 9: E30-E42. CrossRef
22. He YL, Sabo R, Riviere GJ, Sunkara G, Leon S, Ligueros-Saylan M, Rosenberg M, Dole WP, Howard D. Effect of the novel oral dipeptidyl peptidase IV inhibitor vildagliptin on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Curr Med Res Opin. 2007; 23: 1131-1138. CrossRef PubMed
23. Digoxin (Lanoxin®) prescribing information. Greenville, NC: GlaxoSmithKline. 2009. Accessed on December 11, 2013. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/label/2010/020405s004lbl.pdf.
24. Levonorgestrel and Ethinyl estradiol (Levora®) prescribing Information. Parsippany, NJ: Watson Pharma, Inc. 2012. Accessed on December 11, 2013. Available at: http://pi.actavis.com/data-stream.asp ? p roduct-group=1254&p=pi&language=E.
25. Wright DH, Herman GA, Maes A, Liu Q, Johnson-Levonas AO, Wagner JA. Multiple doses of sitagliptin, a selective DPP-4 inhibitor, do not meaningfully alter pharmacokinetics and pharmacodynamics of warfarin. J Clin Pharmacol. 2009; 49: 1157-1167. CrossRef PubMed
26. Polidori D, Sha S, Devineni D, Rothenberg P. L. The renal glucose threshold is increased in patients with type 2 diabetes: results from a novel method for measuring the renal threshold [abstract]. The 70th Scientific Session of the American Diabetes Association (ADA). Orlando, FL; 2010.
27. Macha S, Mattheus M, Pinnetti S, Woerle HJ, Broedl UC. Effect of empagliflozin on the steadystate pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers. Clin Drug Investig. 2013; 33: 351-357. CrossRef PubMed
28. Kasichayanula S, Chang M, Liu X, Shyu WC, Griffen SC, LaCreta FP, Boulton DW. Lack of pharmacokinetic interactions between dapagliflozin and simvastatin, valsartan, warfarin, or digoxin. Adv Ther. 2012; 29: 163-177. CrossRef PubMed
29. Macha S, Rose P, Mattheus M, Pinnetti S, Woerle HJ. Lack of drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Diabetes Obes Metab. 2013; 15: 316-323. CrossRef PubMed
30. Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, Haefeli WE. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 2004; 76: 73-84. CrossRef PubMed
31. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA. Drug-drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009; 85: 173-181. CrossRef PubMed
32. Lin JH, Yamazaki M. Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet. 2003; 42: 59-98. CrossRef PubMed
33. Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. J Am Coll Cardiol. 2013; 61: 2495-2502. CrossRef PubMed
34. Macha S, Sennewald R, Rose P, Schoene K, Pinnetti S, Woerle HJ, Broedl UC. Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers. Clin Ther. 2013; 35: 226-235. CrossRef PubMed
35. Reuning RH, Geraets DR. Digoxin. In: Evans WE, Schentag JJ, Jusko WJ (eds). Applied Pharmacokinetics. 2nd edition: Spokane, WA; 1986.
36. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther. 1993; 266: 1620-1625. PubMed
37. Drescher S, Glaeser H, Mürdter T, Hitzl M, Eichelbaum M, Fromm MF. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther. 2003; 73: 223-231. CrossRef PubMed
38. Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [see comments]. Circulation. 1999; 99: 552-557. Cross- Ref PubMed